Biomedical Engineering Reference
In-Depth Information
Monsarrat B., Alvinerie P., Wright M., Dubois J., Gueritte-Voegelein F., Guenard D.,
Donehower R.C. and Rowinsky E.K. (1993), `Hepatic metabolism and biliary
excretion of Taxol in rats and humans', J. Natl. Cancer Inst. Monogr., 15: 39±46.
Muller C.R, Bassani V.L., Pohlmann A.R., Michalowski C.B., Petrovick P.R. and
Guterres S.S. (2000), `Preparation and characterization of spray-dried polymeric
nanocapsules', Drug Develop. Ind. Pharm., 26(3): 343±347.
O'Shaughnessy J., Tjulandin S., Davidson N., Shaw H., Desai N., Hawkins M.J. and
Gradisha W.J. (2003), `ABI-007 (ABRAXANEi), a nanoparticle albumin-bound
(nab) paclitaxel demonstrates superior efficacy vs taxol in MBC: a phase III trial',
Breast Cancer Res. Treat., 82(Suppl 1): 44.
Panyam J. and Labhasetwar V. (2003), `Biodegradable nanoparticles for drug and gene
delivery to cells and tissue', Adv. Drug Deliv. Rev. 55: 329±347.
Rowinsky E.K., Wright M., Monsarrat B., Lesser G.J. and Donehower R.C. (1993),
`Taxol: pharmacology, metabolism and clinical implications', Cancer Surv., 17:
283±304.
Roy I., Ohulchanskyy T.Y., Pudavar H.E., Bergey E.J., Oseroff A.R., Morgan J.,
Dougherty T.J. and Prasad P.N. (2003), `Ceramic-based nanoparticles entrapping
water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for
photodynamic therapy', J. Am. Chem. Soc., 125(26): 7860±7865.
Salata O.V. (2004) `Applications of nanoparticles in biology and medicine', J.
Nanotechnol., 2: 3.
Shenoy D.B. and Amiji M.M. (2005), `Poly(ethylene oxide)-modified poly(varepsilon-
caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer', Int.
J. Pharm., 293(1±2): 261±270.
Teixerira M., Alonso M.J., Pinto M.M., Barbosa C.M. (2005), `Development and
characterization of PLGA nanospheres and nanocapsules containing xanthone and
3-methoxyxanthone', Eur. J. Pharm. Biopharm., 59(3): 491±500.
Teng Y.K., Lu Z., Wientjes M.G. and Au J.L. (2005), `Formulating paclitaxel
in
nanoparticles alters its disposition', Pharm. Res., 22(6): 867±874.
Torchilin V.P. and Trubetskoy V.S. (1995), `Which polymers can make nanoparticulate
drug carriers long-circulating?', Adv. Drug Deliv. Rev. 16: 141±155.
Velinova M.J., Staffhoorst R.W.H.M., Mulder W.J.M., Dries A.S., Jansen B.A.J., de
Kruijff B. and de Kroon A.I.P.M. (2004), `Preparation and stability of lipid-coated
nanocapsules of cisplatin: anionic phospholipid specificity', Biochim. et Biophys.
Acta, 1663: 135±142.
Walle T., Walle U.K., Kumar G.N. and Bhalla K.N. (1995), `Taxol metabolism and
disposition in cancer patients', Drug Metab. Dispos., 23: 506±512.
Weiss B., Donehower R.C., Wiernik P.H., Ohnuma T., Gralla R.J., Trump D.L., Baker
J.R. Jr, Van Echo D.A., Von Hoff D.D. and Leyland Jones B.
(1990),
`Hypersensitivity reactions from taxol', J. Clin. Oncol., 8: 1263±1268
Wiernik P.H., Schwartz E.L., Strauman J.J., Dutcher J.P., Lipton R.B. and Paietta E.
(1987), `Phase I clinical and pharmacokinetic study of taxol', Cancer Res., 47:
2486±2493.
Yi Y., Kim J.H., Kang H.-W., Oh H.S., Kim S.W. and Seo M.H. (2005), `A polymeric
nanoparticle consisting of mPEG-PLA-Toco and PLMA-COONa as a drug carrier:
improvements in cellular uptake and biodistribution', Pharm. Res., 22 (2): 200±208.
Yu W.P. (1990), `Etude pharmacotechnique et biologique de vecteurs colloidaux d'un
immunomodulateur lipophile: le muramyltripeptide-cholestÂrol (MTP-chol)'. ThÁse
doctorale, No. 160, Universit Paris Sud.
Yu W.P., Wong J.P. and Chang T.M.S.
(1999),
`Biodegradable polylactic acid
Search WWH ::
Custom Search